Journal
CLINICAL IMMUNOLOGY
Volume 129, Issue 1, Pages 163-169Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2008.07.002
Keywords
autoimmune; polyendocrine; syndrome I; interferon omega; radioimmunoassay; autoimmune regulator
Categories
Funding
- The Norwegian Research Council
- EU 6th framework programme (EurAPS)
Ask authors/readers for more resources
Patients with the autoimmune polyendocrine syndrome I (APS I) have high titers of neutralizing IgG autoantibodies against type I interferons (IFNs), in particular IFN-omega. Until now, the most specific assay has been the antiviral interferon neutralizing assay (AVINA), which has the drawbacks of requiring a cytolytic virus, being cumbersome and difficult to standardise. We have developed a fast and reliable immunoassay based on radiolabelled IFN-omega for quantifying anti-IFN-omega antibodies. Sera from 48 APS I patients were analysed together with those from 5 control groups. AIL sera from APS I patients were positive for anti-IFN-omega, while, except one serum, all sera from the controls were negative. This method has the advantage over bioassays that it is readily adapted to high throughput. It provides an alternative, sensitive and specific diagnostic test for APS 1, and an ideal screening tool. to precede mutational analyses of the AIRE gene in suspected APS I cases. (C) 2008 Elsevier Inc. Ail rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available